Galapagos Hit By Atopic Dermatitis Drug Fail
End For IL-7C Inhibitor Partnered With MorphoSys And Novartis
The fundamentals for Galapagos are sound despite the failure of MOR106 for atopic dermatitis and two trials of filgotinib missing their primary endpoints for Sjögren’s syndrome and lupus.
You may also be interested in...
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.
Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is still on the prowl for more.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.